Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy.

Early diagnosis of hepatocellular carcinoma (HCC) has a significant impact on survival by implementation of effective treatment strategies, including hepatic resection, locoregional ablative therapy, and liver transplantation. The use of serum tumor markers and biopsy are particularly important for diagnosis of small hepatic lesions with atypical features on imaging studies. α-Fetoprotein remains the most frequently used tumor marker for the diagnosis of HCC. The development of novel serum biomarkers for HCC, identification of molecular markers for tissue immunohistochemistry, and emergence of new diagnostic techniques such as proteomic profiling may improve the early detection rate of HCC in the future.

[1]  C. Lobe,et al.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. , 2005, Cancer research.

[2]  Shou-Dong Lee,et al.  Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma , 1996 .

[3]  Yoichi M. Ito,et al.  Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size , 2006, The American Journal of Gastroenterology.

[4]  M. Zoli,et al.  Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither? , 2006, The American Journal of Gastroenterology.

[5]  S. Kakar,et al.  Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum , 2008, Modern Pathology.

[6]  G. Grazi,et al.  Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. , 2011, Journal of hepatology.

[7]  S. Kitano,et al.  AFP-Producing Gastric Carcinoma: Multivariate Analysis of Prognostic Factors in 270 Patients , 2003, Oncology.

[8]  A. A. Terentiev,et al.  Structural and functional mapping of α-fetoprotein , 2006, Biochemistry (Moscow).

[9]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[10]  Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma , 2000 .

[11]  Carmen Ayuso,et al.  MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation , 2003, Hepatology.

[12]  L. Forzenigo,et al.  The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis , 2009, Gut.

[13]  B. McMahon,et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.

[14]  M. Colombo,et al.  Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.

[15]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[16]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[17]  B. Daniele,et al.  Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. , 2004, Gastroenterology.

[18]  J. Marrero,et al.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.

[19]  M. Makuuchi,et al.  Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[20]  E. Bass,et al.  Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review , 2002, Hepatology.

[21]  M. Sherman,et al.  Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis , 2007, The American Journal of Gastroenterology.

[22]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[23]  Y. Ueno,et al.  Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. , 2000, The American journal of gastroenterology.

[24]  M. Yeh,et al.  The use of immunohistochemistry in liver tumors. , 2010, Clinics in liver disease.

[25]  T. Roskams,et al.  Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules , 2006, The American journal of surgical pathology.

[26]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[27]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[28]  K. Shiraki,et al.  A clinical study of lectin‐reactive alpha‐fetoprotein as an early indicator of hepatocellular carcinoma in the follow‐up of cirrhotic patients , 1995, Hepatology.

[29]  T. Yip,et al.  Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. , 2003, Clinical chemistry.

[30]  H. Aburatani,et al.  Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma , 2004, Cancer Research.

[31]  E. Keeffe,et al.  Racial differences in effectiveness of α‐fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis , 2002, Hepatology.

[32]  D. Samuel,et al.  Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  M. Bernardi,et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. , 2001, Journal of hepatology.

[34]  L. Bolondi,et al.  The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria , 2010, The American Journal of Gastroenterology.

[35]  M. Kim,et al.  Glypican‐3 is overexpressed in human hepatocellular carcinoma , 2003, Cancer science.

[36]  J. Bruix,et al.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.

[37]  B. Daniele,et al.  α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .

[38]  Y. N. Park,et al.  The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. , 2009, Journal of hepatology.

[39]  Samir Gupta,et al.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.

[40]  H. Otu,et al.  Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease , 2008, Clinical Cancer Research.

[41]  William M. Lee,et al.  Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.

[42]  V. Vilgrain,et al.  Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. , 2001, Journal of hepatology.

[43]  Rita Golfieri,et al.  Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma , 2005, Hepatology.

[44]  Samuel Chang,et al.  Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT. , 2005, AJR. American journal of roentgenology.

[45]  T. Roskams,et al.  Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. , 2010, Seminars in liver disease.

[46]  O John Semmes,et al.  SELDI‐TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma , 2005, Hepatology.

[47]  V. Paradis,et al.  Liver transplantation for hepatocellular carcinoma: Role of biopsy , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[48]  Feng Wang,et al.  Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy , 2010, Journal of Clinical Pathology.

[49]  A. Andriulli,et al.  Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study , 2004, Gut.

[50]  G. Mizejewski,et al.  Alpha-fetoprotein Structure and Function: Relevance to Isoforms, Epitopes, and Conformational Variants , 2001, Experimental biology and medicine.

[51]  Samir Gupta,et al.  Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.

[52]  Raymond T Chung,et al.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. , 2005, Journal of hepatology.

[53]  Pierre Bedossa,et al.  Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases , 2005, Hepatology.

[54]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[55]  Hui Liu,et al.  Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. , 2010, World journal of gastroenterology.

[56]  P. Bejarano.  Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum , 2010 .

[57]  M. Pompili,et al.  Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[58]  A. A. Terentiev,et al.  Structural and functional mapping of alpha-fetoprotein. , 2006, Biochemistry. Biokhimiia.

[59]  Y. Ueno,et al.  Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma , 2000, American Journal of Gastroenterology.

[60]  I. Sartori.  Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein: , 1994 .

[61]  Feng Xie,et al.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. , 2009, World journal of gastroenterology.

[62]  Yusuke Nakamura,et al.  Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. , 2003, Biochemical and biophysical research communications.

[63]  S. D. Lee,et al.  Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. , 1996, Journal of hepatology.

[64]  V. Paradis,et al.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. , 2006, Human pathology.